The COVID-19 VaccinE Response and Co-Administration in Rheumatology Patients (COVER-CoAd)

Based on the experience with influenza, pneumococcal, and shingles vaccinations in rheumatic disease populations, it is clear that some disease modifying anti-rheumatic drugs and the immunomodulatory therapies used to treat immune-mediated inflammatory diseases have the capacity to blunt immune responses to COVID-19 vaccines. Several studies have suggested that patients with autoimmune conditions may be at increased risk of poor COVID-19 outcomes. There is an urgent need to better clarify the immunogenicity and safety of COVID-19 vaccines in people living with rheumatic disease who use immunomodulatory therapies. Boosters at annual or other frequency are available, and there is a need to understand whether these vaccines can be given concurrently with other routine vaccines.

NCT Number	NCT05543642
Lead Sponsor	Oregon Health and Science University
Conditions	Rheumatic Diseases
Enrollment	129 participants
Start Date	2022-10-11
Primary Completion	2025-04-01 (estimated)
Study Completion	2026-08 (estimated)
Updated on ClinicalTrials.gov	2026-05-06